Vitreoretinopathy disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: VTR007 MIFTS: 48	Vitreoretinopathy Categories: Eye diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Vitreoretinopathy

MalaCards integrated aliases for Vitreoretinopathy:

Name: Vitreoretinopathy ⁵⁹ ²⁹ ⁶

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases

See all MalaCards categories (disease lists)

Orphanet: ⁵⁹

Rare eye diseases

External Ids:

Orphanet ⁵⁹ ORPHA98668

Sources

Summaries for Vitreoretinopathy

MalaCards based summary : Vitreoretinopathy is related to wagner syndrome and exudative vitreoretinopathy 1. An important gene associated with Vitreoretinopathy is TSPAN12 (Tetraspanin 12), and among its related pathways/superpathways are ERK Signaling and PI3K-Akt signaling pathway. The drugs Isotretinoin and Bupivacaine have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are cardiovascular system and hearing/vestibular/ear

Sources

Related Diseases for Vitreoretinopathy

Diseases related to Vitreoretinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 191)

#	Related Disease	Score	Top Affiliating Genes
1	wagner syndrome	33.8	VCAN COL2A1
2	exudative vitreoretinopathy 1	33.2	ZNF408 TSPAN12 PRSS23 NDP LRP5 FZD4
3	norrie disease	31.2	TSPAN12 NDP LRP5 FZD4
4	retinal vascular disease	31.0	ZNF408 TSPAN12 NDP LRP5 FZD4
5	persistent hyperplastic primary vitreous	30.9	TSPAN12 NDP FZD4
6	leukocoria	30.9	NDP LRP5 FZD4
7	retinal detachment	30.9	TSPAN12 NDP LRP5 FZD4 CTNNB1 COL2A1
8	exudative vitreoretinopathy	30.8	ZNF408 TSPAN12 RCBTB1 PRSS23 NDP LRP5
9	vitreous syneresis	30.7	VCAN COL2A1
10	osteoporosis-pseudoglioma syndrome	30.4	NDP LRP5 FZD4 CTNNB1
11	coats disease	30.4	TSPAN12 RCBTB1 NDP LRP5 FZD4
12	vitreoretinal dystrophy	30.1	VCAN COL2A1
13	vitreoretinopathy, neovascular inflammatory	12.9
14	wagner vitreoretinopathy	12.7
15	exudative vitreoretinopathy 2, x-linked	12.7
16	exudative vitreoretinopathy 4	12.7
17	exudative vitreoretinopathy 5	12.7
18	exudative vitreoretinopathy 6	12.6
19	exudative vitreoretinopathy 3	12.6
20	exudative vitreoretinopathy 7	12.5
21	vcan-related vitreoretinopathy	12.3
22	syndromic vitreoretinopathy	12.1
23	isolated vitreoretinopathy	12.1
24	microcephaly with or without chorioretinopathy, lymphedema, or mental retardation	11.5
25	microvascular complications of diabetes 5	10.7
26	microvascular complications of diabetes 1	10.7
27	microvascular complications of diabetes 2	10.7
28	macular holes	10.7
29	uveitis	10.6
30	yemenite deaf-blind hypopigmentation syndrome	10.5
31	myopia	10.5
32	macular retinal edema	10.5
33	cataract	10.5
34	retinal disease	10.5
35	eye disease	10.5
36	ndp-related retinopathies	10.4
37	preretinal fibrosis	10.4
38	vitreous detachment	10.4
39	retinal degeneration	10.4
40	keratopathy	10.3
41	neovascular glaucoma	10.3
42	blind hypotensive eye	10.3
43	vitreoretinal degeneration	10.3
44	intraocular pressure quantitative trait locus	10.3
45	microcephaly	10.3
46	eye degenerative disease	10.2	FZD4 COL2A1
47	retinoblastoma	10.2
48	persistent hyperplastic primary vitreous, autosomal recessive	10.2
49	familial retinoblastoma	10.2
50	hydrops, lactic acidosis, and sideroblastic anemia	10.2

Graphical network of the top 20 diseases related to Vitreoretinopathy:

Sources

Symptoms & Phenotypes for Vitreoretinopathy

MGI Mouse Phenotypes related to Vitreoretinopathy:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.02	ABCA4 COL2A1 CTNNB1 FZD4 IL6 LRP5
2	hearing/vestibular/ear	MP:0005377	9.73	COL2A1 CTNNB1 FZD4 NDP TP53 TSPAN12
3	pigmentation	MP:0001186	9.63	ABCA4 CTNNB1 FZD4 LRP5 NDP TP53
4	skeleton	MP:0005390	9.56	ABCA4 COL2A1 CTNNB1 IL6 LRP5 NDP
5	vision/eye	MP:0005391	9.28	ABCA4 COL2A1 CTNNB1 FZD4 IL6 LRP5

Sources

Drugs & Therapeutics for Vitreoretinopathy

Drugs for Vitreoretinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Isotretinoin

Approved

Phase 4

4759-48-2

5282379 5538

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Dermatologic Agents

Phase 4

Anesthetics, Local

Phase 4

Central Nervous System Depressants

Phase 4

Anesthetics

Phase 4

Colchicine

Approved

Phase 3

64-86-8

6167 2833

Heparin

Approved, Investigational

Phase 3

9005-49-6

46507594 772

Fluorouracil

Approved

Phase 3

51-21-8

3385

Dalteparin

Approved

Phase 3

9005-49-6

Triamcinolone

Approved, Vet_approved

Phase 3

124-94-7

31307

Ranibizumab

Approved

Phase 3

347396-82-1

459903

Calcium

Approved, Nutraceutical

Phase 3

7440-70-2

271

Vitamin C

Approved, Nutraceutical

Phase 3

50-81-7

54670067 5785

Tubulin Modulators

Phase 3

Antimitotic Agents

Phase 3

Antirheumatic Agents

Phase 3

Hormone Antagonists

Phase 3

Fibrinolytic Agents

Phase 3

glucocorticoids

Phase 3

Anti-Inflammatory Agents

Phase 3

Hormones

Phase 3

Heparin, Low-Molecular-Weight

Phase 3

Anticoagulants

Phase 3

calcium heparin

Phase 3

Calcium, Dietary

Phase 3

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 3

Angiogenesis Inhibitors

Phase 3

Angiogenesis Modulating Agents

Phase 3

triamcinolone acetonide

Phase 3

Triamcinolone hexacetonide

Phase 3

Triamcinolone diacetate

Phase 3

Immunologic Factors

Phase 3

Immunosuppressive Agents

Phase 3

Pharmaceutical Solutions

Phase 3

Antimetabolites

Phase 3

Antimetabolites, Antineoplastic

Phase 3

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

Antineoplastic Agents, Immunological

Phase 2

Timolol

Approved

26839-75-8

33624 5478

Dorzolamide

Approved

120279-96-1

3154 5284549

Bimatoprost

Approved, Investigational

155206-00-1

5311027

Dexamethasone

Approved, Investigational, Vet_approved

50-02-2

5743

Dexamethasone acetate

Approved, Investigational, Vet_approved

1177-87-3

Racepinephrine

Approved

Early Phase 1

329-65-7

838

Epinephrine

Approved, Vet_approved

Early Phase 1

51-43-4

5816

Iodine

Approved, Investigational

7553-56-2

807

Povidone-iodine

Approved

25655-41-8

Povidone

Approved

9003-39-8

Maleic acid

Experimental, Investigational

110-17-8, 110-16-7

444972

Interventional clinical trials:

(show all 35)

#	Name	Status	NCT ID	Phase	Drugs
1	Determining the Effect of Low-dose Isotretinoin on Proliferative Vitreoretinopathy	Completed	NCT01445028	Phase 4	Isotretinoin
2	The Effects of Triamcinolone Acetonide With Retrobulbar Anesthesia on Postoperative Pain Control Following Vitreoretinal Surgery	Completed	NCT01995045	Phase 4	Triamcinolone;Bupivicaine Hydrochloride
3	Efficacy of Oral Colchicine in Prevention of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment	Unknown status	NCT00370201	Phase 3	colchicine
4	Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR)	Unknown status	NCT00370760	Phase 3	oral colchicine, dexamethasone, low molecular weight heparin, 5-FU;placebo
5	The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR	Unknown status	NCT00371020	Phase 3	low molecular weight heparin, 5-FU
6	Comparison of Two High-Density Silicone Oils in Complicated Rhegmatogenous Retinal Detachment	Unknown status	NCT00403702	Phase 2, Phase 3	Oxane HD [oil-RMN3-mixture];Densiron [(F6H8)
7	Surgical Management of Pseudophakic and Aphakic Retinal Detachment; a Randomized Clinical Trial	Unknown status	NCT00370279	Phase 3
8	25-Gauge Vitrectomy Combine With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in Chinese Patients	Unknown status	NCT02328118	Phase 2, Phase 3	Ranibizumab;Triamcinolone Acetonide
9	Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy	Completed	NCT00373282	Phase 3	Triamcinolone acetonide
10	The Silicone Study	Completed	NCT00000140	Phase 3	Perfluoropropane;Sulfur Hexafluoride;Silicone Oil
11	Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy	Completed	NCT00445003	Phase 3	Ranibizumab;Triamcinolone Acetonide
12	Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.	Recruiting	NCT02834559	Phase 3	5-fluorouracil and low molecular weight heparin;Placebo
13	A Phase 3 Multi-centre Double-masked Randomised Controlled Trial of Adjunctive Intraocular and Periocular Steroid (Triamcinolone Acetonide) Versus Standard Treatment in Eyes Undergoing Vitreoretinal Surgery for Open Globe Trauma.	Recruiting	NCT02873026	Phase 3	Triamcinolone Acetonide
14	25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China: a Randomized, Single Blind Trial	Recruiting	NCT02447185	Phase 3	Ranibizumab;Triamcinolone Acetonide
15	Intravitreal Decorin Preventing Proliferative Vitreoretinopathy in Perforating Injuries: a Pilot Study.	Completed	NCT02865031	Phase 1, Phase 2	Decorin
16	A Pilot Study of Peribulbar Triamcinolone Acetonide for Diabetic Macular Edema	Completed	NCT00369486	Phase 2	40mg triamcinolone;20mg triamcinolone;40mg triamcinolone + laser;20mg triamcinolone + laser
17	Bevacizumab Against Recurrent Retinal Detachment	Active, not recruiting	NCT02192970	Phase 2	Bevacizumab
18	Evaluation Use Optical Coherence Tomography - Rescan During Dissection of Macular Membranes : Pre and Post Operative Aspects	Unknown status	NCT02748421
19	Comparison of Two Techniques for Epiretinal or Internal Limiting Membrane Peel.	Unknown status	NCT00892619
20	Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery: Randomised Clinical Trial of Safety	Unknown status	NCT01959568
21	A Prospective Pilot Study Evaluating the Effect of Intravitreal Injection of Bevacizumab on Recurrent Retinal Detachment Due to Proliferative Vitreoretinopathy	Completed	NCT01860586		Bevacizumab
22	Outcomes of Vitrectomy in Pediatric Retinal Detachment With Proliferative Vitreoretinopathy	Completed	NCT03208205
23	A Prospective, Randomized Study Comparing 1000 Centistoke and 5000 Centistoke Silicone Oil Tamponade for Repair of Proliferative Vitreoretinopathy Retinal Detachments and Diabetic Tractional Retinal Detachments	Completed	NCT01255293
24	Comparison of Vitrectomy Without Internal Limiting Membrane Peeling Versus Inverted ILM Flap Technique for Macular Hole Retinal Detachment in Highly Myopic Eyes	Completed	NCT04011007
25	Familial Exudative Vitreoretinopathy Clinical and Molecular Studies	Completed	NCT00106756
26	Emulsification of Different Viscosity Silicone Oil After Complicated Retinal Detachment Surgery: A Randomized Double-masked Clinical Trial	Completed	NCT02988583
27	The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy	Completed	NCT01255306		Local medical treatment of raised intraocular pressure
28	Plasma Levels of Matrix Metalloproteinases and Degree of DNA Fragmentation in Patients With Pseudoexfoliation Syndrome and Open-Angle Glaucoma (PEXG)	Completed	NCT00327613
29	Adrenocorticotropic Hormone for Intraocular Inflammation in Post-operative Proliferative Vitreoretinopathy Patients	Recruiting	NCT03727776	Early Phase 1	Adrenocorticotropic Hormone
30	An Observational Study of Retinal Function and Structure After Repair of Macula-involving Retinal Detachment Complicated by Proliferative Vitreoretinopathy (RDPVR) Using Adaptive Optics	Recruiting	NCT03551574
31	Visual Outcome Evaluation and Genetic Analysis: Shanghai High Myopia Study	Recruiting	NCT03062085
32	Silicone Oil Versus Long-acting Gas Tamponade in Proliferative Diabetic Retinopathy Patients With High-grade Vitreoretinal Adhesion Undergoing Vitrectomy	Recruiting	NCT03660384
33	Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases	Recruiting	NCT02688309		Ozurdex
34	A Randomized Controlled Trial Comparing Pneumatic Retinopexy Versus Vitrectomy for the Management of Primary Retinal Detachment in Patients With Extended Criteria; Anatomical Success, Functional Success and Impact on Patient Quality of Life	Not yet recruiting	NCT02871531
35	Surgical Retinotomy for the Treatment of Glaucoma	Not yet recruiting	NCT03798145

Search NIH Clinical Center for Vitreoretinopathy

Sources

Genetic Tests for Vitreoretinopathy

Genetic tests related to Vitreoretinopathy:

#	Genetic test	Affiliating Genes
1	Vitreoretinopathy ²⁹

Sources

Anatomical Context for Vitreoretinopathy

MalaCards organs/tissues related to Vitreoretinopathy:

⁴¹

Eye, Retina, Endothelial, Monocytes, Bone, Smooth Muscle, Cortex

Sources

Publications for Vitreoretinopathy

Articles related to Vitreoretinopathy:

(show top 50) (show all 2991)

#	Title	Authors	PMID	Year
1	Inactive Cas9 blocks vitreous-induced expression of Mdm2 and proliferation and survival of retinal pigment epithelial cells. ³⁸	Chen N...Lei H	31278903	2019
2	Early vitrectomy to reverse macular dragging in a one-month-old boy with familial exudative vitreoretinopathy. ³⁸	Iwata A...Kuniyoshi K	31294129	2019
3	Symmetry of folds in FEVR: A genotype-phenotype correlation study. ³⁸	Wang Z...Ding X	31299183	2019
4	Genetic variants of TSPAN12 gene in patients with retinopathy of prematurity. ³⁸	Zhang T...Han M	31009104	2019
5	PEDIATRIC RETINAL DETACHMENT IN AN ASIAN POPULATION WITH HIGH PREVALENCE OF MYOPIA: Clinical Characteristics, Surgical Outcomes, and Prognostic Factors. ³⁸	Tsai ASH...Tan G	30015760	2019
6	Vitreous Wiping, a new technique for removal of vitreous cortex remnants during vitrectomy. ³⁸	van Overdam KA...Manning SS	30536726	2019
7	Vitreoschisis-induced vitreous cortex remnants: missing link in proliferative vitreoretinopathy. ³⁸	van Overdam K	31429189	2019
8	Intraocular application of Mitomycin C to prevent proliferative vitreoretinopathy in perforating and severe intraocular foreign body injuries. ³⁸	Assi A...Cherfan G	30918327	2019
9	CAPN5 genetic inactivation phenotype supports therapeutic inhibition trials. ³⁸	Wert KJ...Mahajan VB	31403230	2019
10	ETIOLOGY AND CLINICAL CHARACTERISTICS OF MACULAR EDEMA IN PATIENTS WITH FAMILIAL EXUDATIVE VITREORETINOPATHY. ³⁸	Rao P...Capone A	31404032	2019
11	Scleral buckling versus vitrectomy for young japanese patients with rhegmatogenous retinal detachment in the era of microincision surgery: real-world evidence from a multicentre study in Japan. ³⁸	Shu I...Gomi F	30741467	2019
12	Secondary pneumatic retinopexy for failed scleral buckle. ³⁸	Balakrishnan D...Oli A	31401580	2019
13	Outcomes after Retinal Detachment Resulting from Self-Inflicted Injury. ³⁸	Liu Q...Stewart JM	31101550	2019
14	PREDICTIVE FACTORS FOR PROLIFERATIVE VITREORETINOPATHY FORMATION AFTER UNCOMPLICATED PRIMARY RETINAL DETACHMENT REPAIR. ³⁸	Xu K...Almeida DRP	29787465	2019
15	Comparative study of penetrating keratoplasty and vitreoretinal surgery with Eckardt temporary keratoprosthesis in ocular trauma versus non-trauma patients. ³⁸	Bove Alvarez M...Garcia-Arumi J	31363832	2019
16	Effect of macrophage migration inhibitory factor on inflammatory cytokines and fibrogenic gene expression in human RPE cells. ³⁸	Qin D...Jin X	31180524	2019
17	Limited Vitrectomy in Patients with Idiopathic Macular Hole ³⁸	Ozkan B...Altintas O	31318187	2019
18	Exome sequencing revealed Notch ligand JAG1 as a novel candidate gene for familial exudative vitreoretinopathy. ³⁸	Zhang L...Yang Z	31273345	2019
19	Multilaminated Vitreomacular Traction in Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy. ³⁸	Han IC...Folk JC	31277800	2019
20	Retinal Vascular Abnormalities in Phakomatosis Pigmentovascularis. ³⁸	Thanos A...Trese MT	31420298	2019
21	Correlating Changes in the Macular Microvasculature and Capillary Network to Peripheral Vascular Pathologic Features in Familial Exudative Vitreoretinopathy. ³⁸	Koulisis N...Nudleman E	31277801	2019
22	CD44 aptamer mediated cargo delivery to lysosomes of retinal pigment epithelial cells to prevent age-related macular degeneration. ³⁸	Chandola C...Neerathilingam M	31080896	2019
23	RECURRENCES OF RETINAL DETACHMENT AFTER RETINECTOMY: Causes and Outcomes. ³⁸	Beuste T...Denion E	31365519	2019
24	[Retinal detachment in children and adolescents. Specific clinical features]. ³⁸	Bier C...Rudolph G	31321489	2019
25	Microscope-Assisted ab externo Surgery for the Treatment of Primary Rhegmatogenous Retinal Detachment - New Tech Meets Old Art. ³⁸	Frisina R...Parolini B	31352453	2019
26	Diagnosis of complicated FEVR preoperatively and intra-/post-operatively: characteristics and risk factors for diagnostic timing. ³⁸	Xia F...Zhao P	31176357	2019
27	Clinical and Genetic Features of Familial Exudative Vitreoretinopathy With Only-Unilateral Abnormalities in a Chinese Cohort. ³⁸	Tian T...Zhao P	31169861	2019
28	Cyclooxygenases inhibitors for preventing the proliferative vitreoretinopathy: Ready for clinical use? ³⁸	Jalalifar S	31182242	2019
29	Long non-coding RNAs in ocular diseases: new and potential therapeutic targets. ³⁸	Zhang L...Xu W	30927500	2019
30	Glaucoma and degenerative vitreoretinopathy in a girl with Nicolaides-Baraitser syndrome. ³⁸	Sethi S...Levin AV	30707941	2019
31	Diagnosis and Management of Familial Exudative Vitreoretinopathy: A Lifelong, Progressive, and Often Asymmetric Disease. ³⁸	Wood EH...Capone A	31169868	2019
32	NOVEL ENDOSCOPE-ASSISTED VITREOUS SURGERY COMBINED WITH ATMOSPHERIC ENDOSCOPIC TECHNIQUE AND/OR SUBRETINAL ENDOSCOPIC TECHNIQUE FOR RHEGMATOGENOUS RETINAL DETACHMENT WITH GRADE C PROLIFERATIVE VITREORETINOPATHY. ³⁸	Kaga T...Ichikawa K	29528982	2019
33	Next-Generation Sequencing in the Familial Exudative Vitreoretinopathy-Associated Rhegmatogenous Retinal Detachment. ³⁸	Chen C...Ding X	31237656	2019
34	Cytokine profiles of phakic and pseudophakic eyes with primary retinal detachment. ³⁸	Garweg JG...Tappeiner C	30561135	2019
35	Ultra-widefield fundus fluorescein angiography in pediatric retinal vascular diseases. ³⁸	Temkar S...Venkatraman V	31124488	2019
36	SUBRETINAL ENDOSCOPIC SURGERY TO TREAT LARGE SUBRETINAL HEMORRHAGES SECONDARY TO AGE-RELATED MACULAR DEGENERATION. ³⁸	Kaga T...Ichikawa K	29370029	2019
37	Intra-silicone Oil Injection of Methotrexate in Retinal Reattachment Surgery for Proliferative Vitreoretinopathy. ³⁸	Falavarjani KG...Alemzadeh SA	31136255	2019
38	Proteomic insight into the pathogenesis of CAPN5-vitreoretinopathy. ³⁸	Velez G...Mahajan VB	31110225	2019
39	Macular Microvascular Findings in Familial Exudative Vitreoretinopathy on Optical Coherence Tomography Angiography. ³⁸	Hsu ST...Vajzovic L	31100165	2019
40	Clinical and molecular characterization of familial exudative vitreoretinopathy associated with microcephaly. ³⁸	Hull S...Michaelides M	31077665	2019
41	Statins in ophthalmology. ³⁸	Ooi KG...Watson SL	30703407	2019
42	Wnt Signaling in vascular eye diseases. ³⁸	Wang Z...Chen J	30513356	2019
43	Endoresection utilizing pars plana vitrectomy for benign and malignant intraocular tumors. ³⁸	Reichstein D...Karan K	30883440	2019
44	TRActional DIabetic reTInal detachment surgery with co-adjuvant intravitreal dexamethasONe implant: the TRADITION STUDY. ³⁸	Iglicki M...International Retina Group (IRG)	31089929	2019
45	IMPACT OF INNER LIMITING MEMBRANE PEELING ON VISUAL RECOVERY AFTER VITRECTOMY FOR PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT INVOLVING THE FOVEA. ³⁸	Garweg JG...Gerhardt C	29394235	2019
46	Proteomic evidence that ABCA4 is vital for traumatic proliferative vitreoretinopathy formation and development. ³⁸	Wang M...Dong H	30738069	2019
47	Mirror image of familial exudative vitreoretinopathy in identical twins. ³⁸	Teke MY...Yavrum F	29492729	2019
48	Hypoxia tolerance in the Norrin-deficient retina and the chronically hypoxic brain studied at single-cell resolution. ³⁸	Heng JS...Nathans J	30988181	2019
49	Adjunctive dexamethasone implant in patients with atopic dermatitis and retinal detachment undergoing vitrectomy and silicone oil tamponade: an interventional case series. ³⁸	Cho AR...Yoon YH	30943922	2019
50	A 21-Year Study of Vitreoretinal Surgery for Aphakic Retinal Detachment: Long-Term Surgical Outcomes and Complications. ³⁸	Bhardwaj G...Muqit MMK	31104986	2019

Sources

Genes for Vitreoretinopathy

Genes related to Vitreoretinopathy (2 elite genes):

(show all 17)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	TSPAN12	Tetraspanin 12	Protein Coding	437.41	Pathogenic ⁶ GeneCards inferred via : Disorders Publications Variants (show sections)
2	ABCA4	ATP Binding Cassette Subfamily A Member 4	Protein Coding	406.56	Pathogenic/Likely pathogenic ⁶ GeneCards inferred via : Publications (show sections)
3	LRP5	LDL Receptor Related Protein 5	Protein Coding	57.13	GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
4	NDP	Norrin Cystine Knot Growth Factor NDP	Protein Coding	56.34	GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
5	FZD4	Frizzled Class Receptor 4	Protein Coding	48.02	GeneCards inferred via : Disorders Publications Gene name Variants (show sections)
6	ZNF408	Zinc Finger Protein 408	Protein Coding	45.36	GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
7	CAPN5	Calpain 5	Protein Coding	44.39	GeneCards inferred via : Disorders Publications Gene name Variants (show sections)
8	VCAN	Versican	Protein Coding	38.14	GeneCards inferred via : Disorders Publications Variants (show sections)
9	CTNNB1	Catenin Beta 1	Protein Coding	35.18	GeneCards inferred via : Disorders Publications Variants (show sections)
10	COL2A1	Collagen Type II Alpha 1 Chain	Protein Coding	24.52	GeneCards inferred via : Publications Variants (show sections)
11	RCBTB1	RCC1 And BTB Domain Containing Protein 1	Protein Coding	24.2	GeneCards inferred via : Publications Variants (show sections)
12	IL6	Interleukin 6	Protein Coding	17.25	GeneCards inferred via : Publications (show sections)
13	KIF11	Kinesin Family Member 11	Protein Coding	16.91	GeneCards inferred via : Publications (show sections)
14	TP53	Tumor Protein P53	Protein Coding	16.91	GeneCards inferred via : Publications (show sections)
15	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	16.76	GeneCards inferred via : Publications (show sections)
16	EVR3	Exudative Vitreoretinopathy 3	Genetic Locus	15.75	GeneCards inferred via : Publications Gene name (show sections)
17	PRSS23	Serine Protease 23	Protein Coding	8.82	GeneCards inferred via : Variants (show sections)

Sources

Variations for Vitreoretinopathy

ClinVar genetic disease variations for Vitreoretinopathy:

⁶ (show top 50) (show all 160)

#	Gene	Variation	Type	Significance	SNP ID	GRCh37 Pos	GRCh38 Pos
1	TSPAN12	NM_012338.4(TSPAN12): c.100del (p.Trp34fs)	deletion	Pathogenic	rs1554403767	7:120480130-120480130	7:120840076-120840076
2	ABCA4	NM_000350.3(ABCA4): c.6089G> A (p.Arg2030Gln)	single nucleotide variant	Pathogenic/Likely pathogenic	rs61750641	1:94471055-94471055	1:94005499-94005499
3	LRRC32	NM_005512.2(LRRC32): c.1630C> T (p.Arg544Ter)	single nucleotide variant	Likely pathogenic		11:76371007-76371007	11:76659963-76659963
4	LRP5	NM_002335.4(LRP5): c.2090A> G (p.Lys697Arg)	single nucleotide variant	Likely pathogenic		11:68174280-68174280	11:68406812-68406812
5	ABCA4	NM_000350.3(ABCA4): c.5908C> T (p.Leu1970Phe)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs28938473	1:94473287-94473287	1:94007731-94007731
6	VCAN	NM_004385.5(VCAN): c.5859G> T (p.Thr1953=)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs80028865	5:82834681-82834681	5:83538862-83538862
7	VCAN	NM_004385.5(VCAN): c.6767T> C (p.Leu2256Pro)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs146630369	5:82835589-82835589	5:83539770-83539770
8	VCAN	NM_004385.5(VCAN): c.6902T> G (p.Phe2301Cys)	single nucleotide variant	Conflicting interpretations of pathogenicity	rs160278	5:82835724-82835724	5:83539905-83539905
9	VCAN	NM_004385.5(VCAN): c.-135G> A	single nucleotide variant	Uncertain significance	rs886060814	5:82767714-82767714	5:83471895-83471895
10	VCAN	NM_004385.5(VCAN): c.930G> A (p.Val310=)	single nucleotide variant	Uncertain significance	rs886060818	5:82808103-82808103	5:83512284-83512284
11	VCAN	NM_004385.5(VCAN): c.2937C> T (p.Pro979=)	single nucleotide variant	Uncertain significance	rs886060819	5:82817062-82817062	5:83521243-83521243
12	VCAN	NM_004385.5(VCAN): c.3067A> G (p.Thr1023Ala)	single nucleotide variant	Uncertain significance	rs886060820	5:82817192-82817192	5:83521373-83521373
13	VCAN	NM_004385.5(VCAN): c.3956A> G (p.His1319Arg)	single nucleotide variant	Uncertain significance	rs886060822	5:82818081-82818081	5:83522262-83522262
14	VCAN	NM_004385.5(VCAN): c.4236T> C (p.Asn1412=)	single nucleotide variant	Uncertain significance	rs752922531	5:82833058-82833058	5:83537239-83537239
15	VCAN	NM_004385.5(VCAN): c.4248C> T (p.Leu1416=)	single nucleotide variant	Uncertain significance	rs758617685	5:82833070-82833070	5:83537251-83537251
16	VCAN	NM_004385.5(VCAN): c.-75A> G	single nucleotide variant	Uncertain significance	rs886060816	5:82767774-82767774	5:83471955-83471955
17	VCAN	NM_004385.5(VCAN): c.5482C> T (p.Pro1828Ser)	single nucleotide variant	Uncertain significance	rs886060823	5:82834304-82834304	5:83538485-83538485
18	VCAN	NM_004385.5(VCAN): c.8058A> C (p.Leu2686Phe)	single nucleotide variant	Uncertain significance	rs780717994	5:82836880-82836880	5:83541061-83541061
19	VCAN	NM_004385.5(VCAN): c.8064C> T (p.Pro2688=)	single nucleotide variant	Uncertain significance	rs886060827	5:82836886-82836886	5:83541067-83541067
20	VCAN	NM_004385.5(VCAN): c.5801T> G (p.Phe1934Cys)	single nucleotide variant	Uncertain significance	rs886060824	5:82834623-82834623	5:83538804-83538804
21	VCAN	NM_004385.5(VCAN): c.7035G> A (p.Thr2345=)	single nucleotide variant	Uncertain significance	rs200757689	5:82835857-82835857	5:83540038-83540038
22	VCAN	NM_004385.5(VCAN): c.905_912del	deletion	Uncertain significance	rs886060834	5:82877158-82877165	5:83581339-83581346
23	VCAN	NM_004385.5(VCAN): c.*1031T> C	single nucleotide variant	Uncertain significance	rs548595991	5:82877284-82877284	5:83581465-83581465
24	VCAN	NM_004385.5(VCAN): c.*1091C> T	single nucleotide variant	Uncertain significance	rs886060836	5:82877344-82877344	5:83581525-83581525
25	VCAN	NM_004385.5(VCAN): c.-259C> T	single nucleotide variant	Uncertain significance	rs886060813	5:82767590-82767590	5:83471771-83471771
26	VCAN	NM_004385.5(VCAN): c.109T> G (p.Ser37Ala)	single nucleotide variant	Uncertain significance	rs142740596	5:82785955-82785955	5:83490136-83490136
27	VCAN	NM_004385.5(VCAN): c.3103T> G (p.Phe1035Val)	single nucleotide variant	Uncertain significance	rs886060821	5:82817228-82817228	5:83521409-83521409
28	VCAN	NM_004385.5(VCAN): c.5427C> T (p.His1809=)	single nucleotide variant	Uncertain significance	rs779803420	5:82834249-82834249	5:83538430-83538430
29	VCAN	NM_004385.5(VCAN): c.6201A> G (p.Glu2067=)	single nucleotide variant	Uncertain significance	rs780184359	5:82835023-82835023	5:83539204-83539204
30	VCAN	NM_004385.5(VCAN): c.7895C> T (p.Thr2632Ile)	single nucleotide variant	Uncertain significance	rs767660495	5:82836717-82836717	5:83540898-83540898
31	VCAN	NM_004385.5(VCAN): c.8063C> T (p.Pro2688Leu)	single nucleotide variant	Uncertain significance	rs755806449	5:82836885-82836885	5:83541066-83541066
32	VCAN	NM_004385.5(VCAN): c.8454G> A (p.Ala2818=)	single nucleotide variant	Uncertain significance	rs773474075	5:82837276-82837276	5:83541457-83541457
33	VCAN	NM_004385.5(VCAN): c.883_885del	deletion	Uncertain significance	rs886060832	5:82877136-82877138	5:83581317-83581319
34	VCAN	NM_004385.5(VCAN): c.898_905delinsG	indel	Uncertain significance	rs886060833	5:82877151-82877158	5:83581332-83581339
35	VCAN	NM_001164097.1(VCAN): c.-334C> T	single nucleotide variant	Uncertain significance	rs886060812	5:82767515-82767515	5:83471696-83471696
36	VCAN	NM_004385.5(VCAN): c.-89T> C	single nucleotide variant	Uncertain significance	rs886060815	5:82767760-82767760	5:83471941-83471941
37	VCAN	NM_004385.5(VCAN): c.297G> C (p.Gly99=)	single nucleotide variant	Uncertain significance	rs886060817	5:82786143-82786143	5:83490324-83490324
38	VCAN	NM_004385.5(VCAN): c.5836C> T (p.His1946Tyr)	single nucleotide variant	Uncertain significance	rs886060825	5:82834658-82834658	5:83538839-83538839
39	VCAN	NM_004385.5(VCAN): c.3204C> T (p.Gly1068=)	single nucleotide variant	Uncertain significance	rs142805131	5:82817329-82817329	5:83521510-83521510
40	VCAN	NM_004385.5(VCAN): c.3264A> G (p.Pro1088=)	single nucleotide variant	Uncertain significance	rs767745674	5:82817389-82817389	5:83521570-83521570
41	VCAN	NM_004385.5(VCAN): c.*2C> T	single nucleotide variant	Uncertain significance	rs370984795	5:82876255-82876255	5:83580436-83580436
42	VCAN	NM_004385.5(VCAN): c.*446T> C	single nucleotide variant	Uncertain significance	rs886060829	5:82876699-82876699	5:83580880-83580880
43	VCAN	NM_004385.5(VCAN): c.881_883del	deletion	Uncertain significance	rs886060831	5:82877134-82877136	5:83581315-83581317
44	VCAN	NM_004385.5(VCAN): c.*905A> G	single nucleotide variant	Uncertain significance	rs796702160	5:82877158-82877158	5:83581339-83581339
45	VCAN	NM_004385.5(VCAN): c.*909del	deletion	Uncertain significance	rs886060835	5:82877162-82877162	5:83581343-83581343
46	VCAN	NM_004385.5(VCAN): c.*1408G> A	single nucleotide variant	Uncertain significance	rs886060837	5:82877661-82877661	5:83581842-83581842
47	VCAN	NM_004385.5(VCAN): c.6169A> C (p.Arg2057=)	single nucleotide variant	Uncertain significance	rs886060826	5:82834991-82834991	5:83539172-83539172
48	VCAN	NM_004385.5(VCAN): c.*160A> G	single nucleotide variant	Uncertain significance	rs886060828	5:82876413-82876413	5:83580594-83580594
49	VCAN	NM_004385.5(VCAN): c.813_816dup	duplication	Uncertain significance	rs140261411	5:82877066-82877069	5:83581247-83581250
50	VCAN	NM_004385.5(VCAN): c.9481C> G (p.Leu3161Val)	single nucleotide variant	Uncertain significance	rs765359111	5:82843891-82843891	5:83548072-83548072

Sources

Expression for Vitreoretinopathy

Search GEO for disease gene expression data for Vitreoretinopathy.

Sources

Pathways for Vitreoretinopathy

Pathways related to Vitreoretinopathy according to GeneCards Suite gene sharing:

(show all 18)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.62	VCAN TP53 LRP5 IL6 FZD4 CXCL8
2	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.8	TP53 IL6 FZD4 CTNNB1 COL2A1
3	Pathways in cancer ³⁷	12.36	TP53 LRP5 IL6 FZD4 CXCL8 CTNNB1
4	WNT Signaling ⁶⁴	12.18	TP53 LRP5 FZD4 CTNNB1
5	Wnt Signaling Pathway and Pluripotency ¹ Show member pathways Wnt Signaling Pathway ¹	12.09	TP53 LRP5 FZD4 CTNNB1
6	Human T-cell leukemia virus 1 infection ³⁷	12.07	TP53 IL6 FZD4 CTNNB1
7	Wnt Signaling Pathways: beta-Catenin-dependent Wnt Signaling ⁶⁵ Show member pathways Basal cell carcinoma ³⁷ Wnt signaling pathway ³⁷	12.05	TP53 LRP5 FZD4 CTNNB1
8	Cell cycle Cell cycle (generic schema) ²² Show member pathways Cell cycle Regulation of G1/S transition (part 2) ²² G0 and Early G1 ⁶⁶ G2 Phase ⁶⁶	11.79	TP53 LRP5 FZD4 CTNNB1
9	Interleukin-4 and 13 signaling ⁶⁶	11.78	TP53 IL6 CXCL8
10	Glioblastoma Multiforme ⁶⁴	11.75	TP53 FZD4 CTNNB1
11	Senescence and Autophagy in Cancer ¹	11.71	TP53 IL6 CXCL8
12	Colorectal Cancer Metastasis ⁶⁴	11.57	TP53 LRP5 IL6 FZD4 CTNNB1
13	Glucocorticoid receptor regulatory network ¹	11.55	TP53 IL6 CXCL8
14	Regulation of Wnt-mediated beta catenin signaling and target gene transcription ¹	11.48	VCAN CXCL8 CTNNB1
15	Cell adhesion_ECM remodeling ²²	11.33	VCAN CXCL8 COL2A1
16	Hepatitis C and Hepatocellular Carcinoma ¹	11.21	TP53 IL6 CXCL8
17	Spinal Cord Injury ¹	11.1	VCAN TP53 IL6 CXCL8 COL2A1
18	Overview of nanoparticle effects ¹	10.85	IL6 CXCL8

Sources

GO Terms for Vitreoretinopathy

Cellular components related to Vitreoretinopathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	endoplasmic reticulum lumen	GO:0005788	9.26	VCAN PRSS23 IL6 COL2A1
2	Wnt signalosome	GO:1990909	8.62	LRP5 CTNNB1

Biological processes related to Vitreoretinopathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription, DNA-templated	GO:0045893	9.85	TP53 NDP LRP5 IL6 FZD4 CTNNB1
2	positive regulation of osteoblast differentiation	GO:0045669	9.63	LRP5 IL6 CTNNB1
3	regulation of angiogenesis	GO:0045765	9.5	TSPAN12 IL6 CTNNB1
4	gastrulation with mouth forming second	GO:0001702	9.48	LRP5 CTNNB1
5	positive regulation of DNA-binding transcription factor activity	GO:0051091	9.46	NDP IL6 FZD4 CTNNB1
6	retinal blood vessel morphogenesis	GO:0061304	9.43	LRP5 FZD4
7	retina vasculature morphogenesis in camera-type eye	GO:0061299	9.4	NDP FZD4
8	Wnt signaling pathway	GO:0016055	9.35	TSPAN12 NDP LRP5 FZD4 CTNNB1
9	extracellular matrix-cell signaling	GO:0035426	9.26	NDP FZD4
10	canonical Wnt signaling pathway	GO:0060070	8.92	NDP LRP5 FZD4 CTNNB1

Molecular functions related to Vitreoretinopathy according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	Wnt-activated receptor activity	GO:0042813	8.8	TSPAN12 LRP5 FZD4

Sources

Sources for Vitreoretinopathy

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ TGDB

⁷¹ Tocris

⁷² UMLS

⁷³ UMLS via Orphanet

⁷⁴ UniProtKB/Swiss-Prot

⁷⁵ Wikipedia